Skip to content

Difamilast

Drug profile

Also known as: MM36, moizerto, OPA-15406

OnpPMDA approved

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Difamilast is an onp drug catalogued in DrugCentral. It was first approved by the PMDA in 2021. DrugCentral lists 1 molecular target, including PDE4B. Recorded indications include Atopic dermatitis.

  • Approval status: onp (first approved 2021 by the PMDA).
  • Molecular targets: PDE4B (1 listed in DrugCentral).
  • Indications: Atopic dermatitis.
  • Molecular formula: C23H24F2N2O5; molecular weight 446.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Atopic dermatitis

Mechanism & targets

Molecular targets (1)

TargetGeneActionActivity
cAMP-specific 3',5'-cyclic phosphodiesterase 4BPDE4BinhibitorIC50 7.95

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2021-09-27PMDA—OTSUKA PHARMACEUTICAL Co., Ltd

Chemical structure

Molecular formulaC23H24F2N2O5
Molecular weight446.45 g/mol
CAS number937782-05-3
InChIKeyVFBILHPIHUPBPZ-UHFFFAOYSA-N
PubChem CID57855696
CCOC1=C(C=CC=C1)C(=O)NCC1=COC(=N1)C1=CC(OC(C)C)=C(OC(F)F)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Difamilast used for?

DrugCentral lists the following indications for Difamilast: Atopic dermatitis.

How does Difamilast work?

Its molecular targets in DrugCentral include PDE4B (inhibitor).

When was Difamilast first approved?

Difamilast was first approved by the PMDA in 2021.

What is the chemical formula of Difamilast?

Difamilast has the molecular formula C23H24F2N2O5 and a molecular weight of 446.45 g/mol.

Browse: all drugs starting with D · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2021-09-27
AgencyPMDA
Targets1
Indications1
FormulaC23H24F2N2O5
DrugCentral ID5503
Interactive profile